Rock Springs Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Rock Springs Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,000	Closed	-$3.83M	–	116
2026 Q1	$3.83M	Sell	30,000 -192,000	-86%	-$24M	0.23%	71
2025 Q4	$27.1M	Buy	222,000 +70,250	+46%	+$8.05M	1.39%	25
2025 Q3	$15.2M	Hold	151,750	–	–	0.89%	41
2025 Q2	$12.6M	Buy	+151,750	New	+$12.1M	0.78%	45

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Rock Springs Capital Management's XBI Position: Q2 2026 in Review

Rock Springs Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 30,000 shares — an estimated $3.83M sold.

Rock Springs Capital Management first reported a position in XBI in Q2 2025 and held it in 4 quarters. The position peaked at $27.1M in Q4 2025. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Rock Springs Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
Rock Springs Capital Management sold 30,000 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $3.83M.
Rock Springs Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2025 and held it in 4 quarters.
Rock Springs Capital Management's State Street SPDR S&P Biotech ETF position peaked at $27.1M in Q4 2025.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.